Alembic Pharma Q2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amortization (EBITA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 14% in Q2FY24.

Pranav aminNational list of essential medicineAlembic pharmaNational listEssential medicineAlembic pharma q2 resultsAlembic pharma q2Alembic pharma resultsAlembic pharma q2 earningsAlembic pharma shares